Editorial companion

What stands out

Bloomberg reported that a late-stage melanoma trial of an mRNA vaccine co-developed by Moderna and Merck reduced recurrence, and Wall Street reacted immediately. That matters because late-stage oncology data can flip a speculative program into a commercial opportunity or a long regulatory slog, and this result is precisely the sort of binary outcome investors price in quickly. Watching how each stock trades after the headline shows the gap between headline-driven momentum and the slower work of turning trial success into sustainable sales.